SEC Form 4 · accession 0001415889-17-001636
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glenn Baity
Officer — EVP AND GC
Period of report
Oct 4, 2017
Accepted (ET)
Oct 6, 2017 · 6:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 4, 2017 | M | 6,500 | $1.62 | A | 74,156 | D | |
| Common Stock | Oct 4, 2017 | M | 4,500 | $2.18 | A | 78,656 | D | |
| Common Stock | Oct 5, 2017 | M | 1,000 | $2.18 | A | 79,656 | D | |
| Common Stock | Oct 5, 2017 | M | 7,500 | $1.62 | A | 99,656 | D | |
| Common Stock | Oct 5, 2017 | M | 20,000 | $2.00 | A | 107,156 | D | |
| Common StockF2 | Oct 5, 2017 | S | 37,500 | $40.9078 | D | 69,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.62 | Oct 4, 2017 | M | 6,500 | D | — | Mar 24, 2021 | Common Stock | 6,500 | 7,500 | D |
| Stock Option (right to buy)F4 | $2.18 | Oct 4, 2017 | M | 4,500 | D | — | Mar 22, 2022 | Common Stock | 4,500 | 125,500 | D |
| Stock Option (right to buy)F4 | $2.18 | Oct 5, 2017 | M | 1,000 | D | — | Mar 22, 2022 | Common Stock | 1,000 | 124,500 | D |
| Stock Option (right to buy)F3 | $1.62 | Oct 5, 2017 | M | 7,500 | D | — | Mar 24, 2021 | Common Stock | 7,500 | 0 | D |
| Stock Option (right to buy)F5 | $2.00 | Oct 5, 2017 | M | 20,000 | D | — | Oct 19, 2018 | Common Stock | 20,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2017.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.605 to $41.065 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F325% of the shares subject to the Stock Option vested and became exercisable on March 25, 2012. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
- F425% of the shares subject to the Stock Option vested and became exercisable on March 23, 2013. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
- F550% of the shares subject to the Stock Option vested and became exercisable on October 20, 2010. The remaining shares vested and became exercisable thereafter in 24 equal monthly installments.